St. John Fisher University, Wegmans School of Pharmacy, Rochester, NY, USA.
Novo Nordisk, Inc., Plainsboro Township, NJ, USA.
Am J Pharm Educ. 2023 Aug;87(8):100109. doi: 10.1016/j.ajpe.2023.100109. Epub 2023 May 9.
To assess how obesity is addressed in Doctor of Pharmacy (PharmD) schools and colleges, identify the extent to which core obesity competencies are covered in the curricula, and identify opportunities for expanding obesity management training.
An online survey was conducted with PharmD program leaders in the United States. Respondents answered questions regarding obesity education in their pharmacy school curricula. Data were analyzed in aggregate, using descriptive statistics.
We collected responses from 75 of 150 (50%) PharmD programs. One-third (32%) of respondents thought their graduating students were very prepared to discuss obesity pharmacotherapy (anti-obesity medication) options with patients. A total of 45% reported obesity pharmacological treatment was covered to a great extent. Few respondents (19%) were very familiar with anti-obesity medications; 21% thought their students were similarly familiar. No programs covered weight stigma and discrimination to a great extent. Most respondents (88%) believed obesity education was fairly/very important to include in PharmD curricula, and 96% thought it was similarly appropriate to include. But 72% indicated that expanding obesity education was not a priority/low priority. Lack of room in the curricula was cited as the greatest barrier, with 60% of PharmD programs reporting this to be a large barrier.
Pharmacists, as medication experts, are key members of the care team. However, obesity management/pharmacotherapy is not emphasized in most pharmacy schools. Therefore, pharmacists are not well-prepared to provide counseling on medications for obesity. Leveraging guidance on core obesity competencies and available resources could help expand obesity education in pharmacy schools.
评估药学博士（PharmD）学校如何解决肥胖问题，确定课程涵盖核心肥胖能力的程度，并确定扩大肥胖管理培训的机会。
在美国，对 PharmD 项目负责人进行了在线调查。受访者回答了他们药学学校课程中肥胖教育的问题。使用描述性统计数据对数据进行了汇总分析。
我们从 150 个 PharmD 项目中收集了 75 个（50%）的回复。三分之一（32%）的受访者认为他们的毕业生非常准备好与患者讨论肥胖症药物治疗（抗肥胖药物）的选择。共有 45%的人报告说肥胖症的药理学治疗得到了很大程度的覆盖。很少有受访者（19%）非常熟悉抗肥胖药物；21%的人认为他们的学生也同样熟悉。没有一个项目涵盖了肥胖的耻辱和歧视。大多数受访者（88%）认为肥胖教育在 PharmD 课程中相当/非常重要，96%的人认为这同样合适。但 72%的人表示扩大肥胖教育不是优先事项/低优先级事项。课程中缺乏空间被认为是最大的障碍，60%的 PharmD 项目报告说这是一个很大的障碍。
作为药物专家，药剂师是医疗团队的关键成员。然而，大多数药学学校并没有强调肥胖管理/药物治疗。因此，药剂师在提供肥胖症药物治疗方面的咨询方面准备不足。利用核心肥胖能力的指导和可用资源可以帮助扩大药学学校的肥胖教育。
